Keeps review: is it worth it?

Keeps doesn't invent hair-loss science — it repackages well-established drugs into a convenient subscription. The active ingredients in nearly every Keeps plan are finasteride and minoxidil, both decades old and both heavily studied. So an honest review splits cleanly into two questions: *Do these drugs actually work, and how well?* (yes, with real numbers) and *Is buying them through Keeps a good deal and a safe one?* (often yes on price, with a few caveats). We treat both below as an independent analyst, not as someone who has physically used the service.

What is Keeps and how does the service work?

Keeps is a US direct-to-consumer telehealth brand focused exclusively on hair loss in men (and others assigned male at birth) who are 18 or older. It launched in 2018 and is operated by the telehealth company Thirty Madison, Inc. In late 2025, Remedy Meds, LLC announced an all-stock agreement valued at over $500 million to acquire Thirty Madison, so the corporate parent is changing even though the Keeps consumer brand continues (PRNewswire, Sept. 2025). Keeps itself is a marketing and logistics platform; the actual medicine is handled by independent licensed parties — a physician-owned medical group employs or contracts the clinicians who review cases and write prescriptions, and licensed US pharmacies fill them.

The flow is almost entirely asynchronous, meaning there is typically no live video appointment:

1. You complete a free online consultation about your symptoms and medical history.
2. You upload photos of your scalp and hairline.
3. A provider licensed in your state reviews the intake and, if appropriate, issues a prescription.
4. A partner pharmacy fills it, and treatments ship discreetly on a recurring schedule — commonly every three months, with six- and twelve-month options.

Two structural points shape everything that follows. First, it is a subscription, not a one-off purchase — Keeps bills on a recurring (usually quarterly) basis, which is partly clinical (these drugs take months to show results) but also locks in revenue. Second, Keeps positions itself as the budget option in men's hair loss: it competes most directly with Hims and Roman, and its core pitch is offering the same generic finasteride and minoxidil for less.

How do finasteride and minoxidil actually work?

The two drugs attack male-pattern hair loss (androgenetic alopecia, or AGA) by completely different mechanisms, which is exactly why dermatologists often combine them.

Finasteride is a 5-alpha-reductase type II inhibitor. It blocks the enzyme that converts testosterone into dihydrotestosterone (DHT), the androgen that progressively miniaturizes genetically susceptible scalp follicles. Oral finasteride 1 mg substantially lowers scalp and serum DHT, slowing or halting the hormonal driver of balding (FDA Propecia label). In short, it treats the underlying *cause*.

Minoxidil is a vasodilator originally developed as an oral blood-pressure drug; its hair-growth effect was discovered as a side effect. The precise mechanism is still not fully settled, but it is thought to shorten the resting (telogen) phase, prolong the growth (anagen) phase, and improve blood flow around the follicle. Importantly, minoxidil is a prodrug that must be activated by the enzyme sulfotransferase in the scalp, and people differ in how much of that enzyme they produce — which is a major reason minoxidil transforms results for some men and does almost nothing for others. Minoxidil treats the *follicle*, not the hormone.

Because one drug suppresses DHT and the other stimulates the follicle, using them together is the standard combination approach for men seeking maximum results.

How well do these treatments actually work?

This is where Keeps' value rests, because the drugs — not the brand — do the work. The good news is the evidence base is strong and decades deep.

For finasteride 1 mg, the headline findings most relevant to a man deciding whether to start are:

• In the pivotal long-term data, the dominant benefit is *stopping loss* rather than dramatic regrowth. A widely cited five-year multinational study reported that roughly 90% of men either improved or were unchanged (stable) at five years, while men on placebo continued to lose hair (PMID 11809594). Put bluntly: finasteride's biggest win is preventing the slide, with visible regrowth as a frequent bonus.
• Over a year of treatment, finasteride produces a measurable increase in hair count in a target scalp area, though the absolute gain is modest — typically a net improvement of a couple of dozen hairs per square centimeter region over placebo.
• Roughly 30–50% of men do not show clear regrowth, even though many in that group are still benefiting by maintaining what they have. Results also vary by location: response tends to be strongest at the crown (vertex) and weakest at the frontal hairline.

For topical minoxidil 5%, the most clinically useful realities are:

• Minoxidil is the only topical drug FDA-approved for male AGA (the 2% solution in 1988, the 5% in 1997), and 5% applied twice daily is the most effective over-the-counter option for men.
• Randomized trials consistently show 5% minoxidil increases hair counts versus placebo, but the response is uneven — a substantial share of users (commonly cited around half or more) see little visible improvement, largely because of individual differences in scalp sulfotransferase activity.

The key, honest framing for any prospective Keeps customer: these are maintenance drugs, not cures. Benefits typically take three to six months to become visible, peak around a year, and reverse within months to about a year if you stop. Whatever your hair looks like on treatment is roughly what you'll keep — for as long as you keep taking it.

What does Keeps actually cost?

Keeps' core appeal is price, and its generic-first pricing is genuinely lower than many branded telehealth competitors. Based on Keeps' published plans, the typical structure is:

• Generic finasteride 1 mg: about $45 per quarter, or roughly $150 for a year prepaid.
• Minoxidil 5% (solution or foam): about $60 per quarter.
• Finasteride + minoxidil together: about $105 per quarter, or roughly $360 prepaid annually.
• An annual telehealth consultation is inexpensive (around $5).

Keeps also markets newer compounded multi-ingredient formulations (combination "chew" and topical "drop" products that stack several actives), which cost more than the standalone generics.

The unavoidable benchmark for value: generic finasteride 1 mg is one of the cheapest prescription drugs in existence, frequently available for only a few dollars a month at retail or discount-cash pharmacies, and 5% minoxidil is sold over the counter for similar low prices at any drugstore. Keeps' premium over those raw-drug prices buys you convenience — the online consult, the prescription, and automatic refills shipped to your door. That convenience is real and, for many men, worth it. But it is convenience you are paying for, not a unique medicine. Anyone willing to see a primary-care doctor or use a discount pharmacy card can often get the identical generics for less.

Are the products safe and legitimate?

The regulatory backbone is reassuring: Keeps' core offerings — oral finasteride 1 mg and 5% minoxidil — are FDA-approved drugs with decades of real-world use, prescribed (where required) by state-licensed clinicians and dispensed by licensed US pharmacies. That is a legitimate, mainstream model of care.

The caveats are about *specific products* and *side-effect counseling*, not the company's legitimacy.

Finasteride side effects. In the pivotal clinical trials, sexual side effects — reduced libido, erectile dysfunction, or decreased ejaculate volume — were uncommon, reported in roughly 1–4% of men, only modestly above placebo, and generally reversible on stopping the drug (FDA Propecia label). Beyond the trial data, a more contested issue is post-finasteride syndrome (PFS): reports of sexual, mood, and cognitive symptoms that some men say persist after discontinuation. In 2012 the FDA updated the US Propecia label to note libido, ejaculation, and orgasm disorders that continued after discontinuation. However, PFS remains scientifically disputed and its true prevalence is unknown. In 2022, responding to a long-pending citizen petition, the FDA stated the petition "does not provide reasonable evidence" of a causal link between finasteride and persistent sexual problems, depression, or suicide — while declining to pull the drug from the market — but it did require adding reports of suicidal ideation and behavior to the label. A prudent reading: serious persistent effects appear rare, but they are real enough to warrant informed consent — and an asynchronous online intake should not skip that conversation.

Compounded and topical formulations. This is the single most important safety caveat for any telehealth hair brand, Keeps included. No topical finasteride product is FDA-approved, and in April 2025 the FDA issued an alert warning that compounded topical finasteride — widely marketed online as a supposedly "low-risk" alternative to the pill — can be absorbed systemically and cause the same kinds of side effects as oral finasteride, including sexual dysfunction and neuropsychiatric symptoms, sometimes persisting after stopping (FDA, April 2025). The agency cited 32 adverse-event reports received over 2019–2024, many of which described symptoms continuing after the product was discontinued, and noted that some patients had been told a topical product carried no risk. The practical takeaway: do not assume a topical or compounded multi-ingredient product is automatically "safer" than the standard pill simply because it goes on your scalp. If anything, the best-understood safety profile belongs to the plain, single-ingredient FDA-approved generics — which happen to be Keeps' cheapest options.

Who should not take finasteride at all: women who are or may become pregnant must never handle crushed or broken finasteride tablets, because the drug can cause birth defects in a male fetus (FDA). Keeps' men-only model sidesteps the patient-side issue, but household members should still be aware. Finasteride also lowers PSA, which can complicate prostate-cancer screening — worth flagging to your regular doctor.

Who is Keeps best for — and who should skip it?

Keeps is a good fit if you:

• Are a man in the early-to-middle stages of male-pattern hair loss, where treatment can still preserve and partly restore hair.
• Want a low-friction, low-cost way to start the evidence-based standard of care without a dermatology appointment.
• Value automatic refills and discreet shipping, and prefer to stick with the proven generics rather than premium add-ons.

You should think twice — or look elsewhere — if you:

• Have very advanced baldness with little hair left to save; these drugs maintain and modestly regrow, they do not resurrect dead follicles, and a hair-transplant consult may be more relevant.
• Are particularly concerned about finasteride's sexual or mood side effects and want a thorough, ideally synchronous, conversation before starting — an asynchronous form may not give you that depth.
• Are tempted primarily by compounded multi-ingredient "upgrade" products; given the 2025 FDA alert, the burden of proof is on those formulations, and the cheaper single-ingredient generics have the stronger safety and efficacy record.
• Are comfortable getting a prescription from your own doctor and filling generics at a discount pharmacy, in which case you can likely replicate Keeps' treatment for less money.

How does Keeps compare to the alternatives?

Against Hims, the most direct competitor, the products are largely the same drugs; the differences are price, breadth, and packaging. Keeps is narrowly focused on hair and tends to lead on the price of basic generics, while Hims is a broader men's-health platform. Against Roman/Ro, similar logic applies — comparable medications, different bundling. Across all three telehealth brands, the meaningful variable is rarely *which* finasteride or minoxidil you get (they're interchangeable generics) but *how much you pay* and *whether you're being upsold into a pricier compounded formulation.*

The other real alternative is the non-telehealth route: a visit to a primary-care physician or dermatologist plus generic prescriptions and over-the-counter minoxidil. This is usually the cheapest path and offers the most thorough side-effect counseling, at the cost of convenience and a bit more effort. For men who want minimal friction, Keeps is a reasonable middle ground; for men optimizing strictly for cost or for careful medical oversight, traditional care can win.

The bottom line

Keeps is a legitimate, affordably priced way to access the two treatments that genuinely move the needle on male-pattern hair loss — and on its cheapest, FDA-approved generics, it is one of the better values in the telehealth hair space. The medicine is real, the evidence is strong, and the convenience is meaningful.

But three honest caveats define the smart way to use it. First, these are lifelong maintenance drugs, not cures — stop, and the benefit fades within about a year. Second, the single-ingredient generics are both the cheapest and the best-understood options; the newer compounded multi-ingredient products carry less evidence and, per the FDA's April 2025 topical-finasteride alert, should not be assumed safer than the standard pill. Third, the raw drugs are extremely inexpensive elsewhere, so what you're really paying Keeps for is convenience — a fair trade for many men, but worth recognizing for what it is. If you want to start the standard of care quickly, cheaply, and with auto-refills, Keeps does that job well. Just keep your add-ons minimal and take the finasteride side-effect counseling seriously — ideally with input from a clinician you can actually talk to.